Stifel Nicolaus Sticks to Their Buy Rating for Alkermes (ALKS)
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Alkermes (ALKS – Research Report) today and set a price target of $36.00. The ...
Stifel Nicolaus Keeps Their Buy Rating on Neurogene (NGNE)
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Neurogene (NGNE – Research Report) today and set a price target of $46.00. The ...
MarketBeat on MSN2h
Cybersecurity Stocks Are Soaring-Here's Why These 3 Stand Out
In recent years, the broader technology sector has often been the driving force behind market growth. However, at the start ...